

Annual Report 2023

2023 Highlights

- **Invested** \$10.9 million in 32 companies during 2023, including 18 new companies. Overall, TCA has invested \$304 million in 544 companies since inception in 1997
- Celebrated 396 Members at year end 2023
- Deployed our **annual network funds** which invested \$5.7 million of capital into deals in 2023 (in addition to \$5.2 million from individual member investments) and brought **diversification** to our members
- Realized three exits including one unicorn exit (DTx Pharma) for \$1 billion that yielded a 18x return for the earliest TCA investors. TCA invested over \$2.5 million an amount exceeded by only 12 of TCA's 544 portfolio companies in TCA's history. Some TCA members also served in active roles in management and as advisors
- Achieved 5.8x multiple cumulative return on all outcomes (all exits and shutdowns) since 1997 with IRR of 23.7%
- Implemented a **new strategy** to expand geographically through licensing, build alliances with selected groups, and add an Accelerator for high potential deal flow
- Continued to mentor and guide the 263 companies (48%) that are still active in the portfolio

In 2023 TCA VG had five networks:


- Tech Coast Angels Los Angeles is our largest network, with 136 members. TCA Los Angeles invests in a wide range of businesses in the US primarily with emphasis on technology, adtech, healthtech, media, entertainment, and SaaS. For leadership & member profiles, click here.
- Tech Coast Angels Orange County is where TCA began in 1997 and is comprised of 94 members. TCA Orange County invests in a wide range of businesses in the US and Canada with an emphasis on medical devices, technology, fintech, edtech, healthtech, software, cyber, SaaS, AI, iOT, and some CPG. For leadership & member profiles, click here.
- Pasadena Angels is our second largest network, with 100 members. Pasadena Angels invests at the seed to seed plus stage primarily in California and rest of the US and Canada with an emphasis on technology, fintech, edtech, entertainment, media, CPG and SaaS. For leadership & member profiles, click here.
- Tech Coast Angels Inland Empire covers the area east of Los Angeles including Riverside and San Bernardino, with 11 members. Particular emphasis is on very early seed stage investing, with successful companies then exposed to the other networks within TCA. For leadership & member profiles, click here
- MEDA Angels brings strong expertise in Life Sciences, with 55 members most of whom are doctors, PhDs and healthcare executives. MEDA Angels focuses on healthtech and invests broadly across the sector including digital health, SaaS, medical devices, robotics, diagnostics, wellness and therapeutics (limited to repurposed drugs and biosimilars). Emphasis is on mid-seed and A-Round and can be based anywhere in the US and even foreign-based. For leadership & member profiles, click here.

2023 was a challenging year of initiatives and change at TCA VG (formerly known as Tech Coast Angels)


- Rebranded from Tech Coast Angels to TCA Venture Group to reflect our evolution
 - No longer just "tech" but a diverse set of industries
 - No longer just "coast" (which originally referred to the California coast), but now over 59% of the dollars are invested outside of Southern California
 - No longer just "angels" with half of the investment through funds and with the addition of our licensing program and an accelerator
- Total funding of \$10.9 million was down from \$15.4 million in 2022, reflecting the overall downturn in the market (and one \$3.2 million deal in 2022 which inflated total in that year)
- Took actions to implement strategy changes to position TCA VG for growth:
 - Active efforts to expand into new geographies through licensing, including a new TCA-Southeast network that was publicly announced in early 2024
 - Created a new Accelerator that was publicly announced in early 2024
 - Strengthened Angel Syndication Network pipeline with an additional meeting each month on pre-due diligence deals
 - Provided additional support to our portfolio companies with stronger relationships with VCs

TCA invested \$10.9 million in a total of 32 companies in 2023

- Investment was across a diverse mix of industries showing that TCA continues to invest in both tech and non-tech companies
- Life Sciences was the largest sector (51% of amount) and exceeded half for the first time. Within Life Sciences, Pharma was largest with 29%. SAAS/Software/Data Analytics was largest single vertical with 32% of the amount invested
- 18 of these companies were new additions to the portfolio and 61% of the dollar investment went to these new companies (up from 48% in 2022)




*Life Sciences 51%



Our members, with their extensive and broad industry experience, helped TCA invest with confidence in this diverse range of industries, which has always been part of TCA's DNA


- Of **new** companies added to the portfolio in 2023, Life Sciences and SAAS/Software/Data Analytics continue to lead with 50% and 44% of the companies
- Within Life Sciences, the largest categories among new companies are Pharma (28%), followed by Medical Devices (11%), Medical Diagnostics (6%), and Digital Health (6%)
- Life Sciences has grown to 64% of dollars invested and SAAS/Software/Data Analytics


NUMBER OF TCA INITIAL INVESTMENTS BY INDUSTRY BY YEAR



Our members, with their extensive and broad industry experience, helped TCA invest with confidence in this diverse range of industries

- Combining new and follow-on investment, Life Sciences and SAAS/Software/Data Analytics continue to lead with 51% and 32% of the dollars invested
- Relative to ACA benchmarks, TCA VG invested more in Pharma, SAAS/Software/Data Analytics and Consumer internet, and less in Industrials/BTB, Consumer Products & Services, Financial, IT Hardware and Energy & CleanTech






\$10.9 million in TCA Investment in 2023 shows we continue to fund exciting companies, albeit at a lower pace

- Total investment for the year continues the longest sustained level of high investment activity since TCA was founded in 1997 13 years at \$10 million or more
- From 2011-2023, total TCA investment each year was between \$10 \$21 million
- Five chapter funds and the target of a decision from the funds within 30 days of screening helped drive a strong pipeline. TCA is working diligently to be the Best Place for the Best Companies to get funded
- 61% of investment was into new companies in 2023 (vs 48% in 2022)

TCA NEW & FOLLOW-ON INVESTMENT BY YEAR




^{*} Note NuFund Venture Group was TCA-San Diego prior to 2022

TCA invested in 32 companies in 2023, including 18 new companies

- This total of 32 includes 12 companies in SAAS/Software/Data Analytics, 7 in Pharma, 7 in Medical Devices, 2 in Consumer Products/Services and 1 each in Digital Health, Medical Diagnostics, and Agriculture/Food.
- The 18 new companies included 8 in SAAS/Software/Data Analytics, 5 in Pharma,
 2 in Medical Devices, and 1 each in Digital Health, Medical Diagnostics and
 Consumer Products/Services

NUMBER OF TCA COMPANIES INVESTED IN EACH YEAR




^{*} Note NuFund Venture Group was TCA-San Diego prior to 2022


The TCA Venture Group's five networks combined to fund \$10.9 million into 32 companies

- TCA-OC and Pasadena Angels each led 29% of the deals, followed by TCA-LA (24%) and MEDA Angels (18%)
- In terms of funding, Pasadena led deals accounted for 30% of the funding, followed by TCA-OC (28%), TCA-LA (21%) and MEDA Angels (21%)
- Regardless of the network leading due diligence, all deals were available to all members for investment, and seven companies received funding from more than one network fund





2023 TCA INVESTMENTS BY NETWORK LEAD 32 COMPANIES



TCA had 1 "Home Run" and 2 small exits (and 8 shutdowns) in 2023 dropping the cumulative return to 5.8x on all outcomes since 1997

- DTx Pharma (2018 TCA investment) reached unicorn status and was acquired by Novartis for \$1 billion (\$500 million upfront). Earliest TCA investors received an 18x return (if milestones are achieved) and 63% IRR); TCA ACE Fund-19 San Diego and TCA Ace Fund 3 investors received 14x. TCA invested over \$2.5 million in funding in DTx Pharma, an amount exceeded by only 12 of TCA's 544 portfolio companies in the angel network's history. The combination of large direct investment by members and investment by two of TCA's annual funds resulted in a large number of TCA members participating in the outcome. Several TCA members were active in management roles and as advisors, and made additional direct investment. See TCA VG press release here
- Trials.ai (2019 TCA investment) was acquired by ZS Associates for a 1x return
- Atlazo (2019 TCA investment) was acquired by Nordic Semiconductor (OSL: NOD) for <1x return

This brings the total outcomes since TCA's inception in 1997 to 125 exits, and 156 shutdowns. Of the 544 investments TCA has made since its founding, 263 (48%) are still active. At the highest price achieved after IPOs, **TCA's return** (assuming equal weighting) has been **5.8x** and the **IRR** has been **23.7%**. This compares to 2.5x and 22% benchmarks for angels per Angel Resource Institute. Tax benefits from the write-offs are not included in TCA returns.


TCA's results make it clear that patience is required – with largest exits happening after 5 years or more, and most failures occurring in the "Valley of Death" 2 years to 5 years after investment



The number of exits dropped and shutdowns increased in 2023 due to the current market downturn

- Exits dropped to 3 (the third lowest year since 1999) from 2022's 11 exits. Shutdowns were flat at 8
- Based on previous stock market peaks in 2000 and 2008, exit activity tends to surge just before peaking, followed by a surge in shutdowns just after the peak
- If the stock market continues to rebound, exits should recover





See pages
38 and 39
for Tips for
Entrepreneurs
and Angels
navigating these
challenging
times

TCA invested in 18 new companies in 2023:

Alleviate – products that help people treat their own chronic injuries Arwall - XR/AI virtual production tools for creators, filmmakers, and brands **Essenvia** – regulatory management system for medical device companies **Giftpack.Al** – smart gifting platform for enterprises Honest Game – system that empowers schools to unlock college athletic opportunities Light Line Medical – photo disinfection using visible light to treat catheter infections **LIMBER Prosthetics & Orthotics** – digital fabrication of prosthetics Material - kitchen essentials for the modern home cook Mimivax – clinical Immunotherapy development for neuro-oncology Nested Knowledge – software automating systematic review and meta-analysis for pharma Nuvox *- oxygen therapeutic platform in oncology, CNS, respiratory, and other indications Octagon Therapeutics – pre-clinical biotech company focused on autoimmune disease **ORNA** – end-to-end cyberattack detection and response automation platform for SMBs Pitchit – sales software that leverages AI to enable multichannel conversational commerce RealSeq Biosciences – tech for biomarker discovery, liquid biopsy and single cell analysis Reglagene – reglagene creates therapies for safe and effective treatment of brain diseases **<u>SimGraphics Engineering</u>** – directable AI that delivers 1:1 animated character interactions Trio Pharmaceuticals – enhancing the body's ability to fight against cancer effectively

^{*} TCA investment more than \$1 Million in 2023

TCA made new investments in these 14 portfolio companies:

Amsel Medical – needle-delivered vessel clamping for venous leg ulcers

Berri Organics – plant-based electrolyte hydration solution

Everyset (former Castifi) – onboard background actors, track times, and submit payroll

Forest Devices – EEG-based system using embedded algorithms to identify strokes

Havenlock – security hardware technology company focusing on access control

iPourlt – self-pour tap systems for beer and wine

Karma Biotechnologies – LNP platform, enabling in vivo engineering for oncology

Lumoptik – light guided medical devices

Lynx Biosciences – capture dynamic interactions of tumor cells within immune environment

Magic Links* – E-commerce in social video

Open Sesame Media – platform for productive workforces through online learning

Single Pass – development and marketing of an innovative biopsy closure device


Trusty.care – health SaaS for insurance brokers that matches prospective customers to plans

Tympanogen – non surgical eardrum repair that replaces tympanoplasty

^{*} TCA investment more than \$1 Million in 2023


We are striving for greater diversity in our members and the background of our portfolio company CEOs

- In terms of funding, the percentage going to non-white CEOs has increased steadliy from 18% in 2021 to 21% in 2022 to 30% in 2023
- This minority representation is significantly higher than ACA Benchmarks of 14% in 2022 and 12% in 2023
- Two of our five network Presidents are non-white




Funding of female CEOs was stable in terms of number of companies, but declined in terms of funding

- In terms of funding of non-male CEOs, the amount was flat at 22%, but up from 15% in 2022. In terms of number of companies, the percentage led by non-male CEOs was down slightly to 11% in 2023, compared to 12% in 2022 and 15% in 2021
- Compared to ACA Benchmarks, funding percentage was slightly below ACA benchmarks of 16% in 2023 and 20% in 2022
- Entering 2024, three of TCA's five network Presidents are female



Mix of CEOs with prior experience as CEO decreased in 2023

- 36% of funding in 2023 was for companies led by CEOs with previous experience as CEO, down from 53% in 2022
- This compares to the ACA Benchmark of 32%
- This is concerning, since recent studies by other angel groups have shown higher returns for CEOs with previous experience click here
- We will be studying this for TCA's porfolio in the coming year



TCA's Angel Syndication Network (ASN) covers 60+ angel groups

- These angel groups nominate their best deals to share with other angel groups for syndication
- ASN hosts two monthly "virtual" web presentations one where the deals have been funded by another group AND one which shares high potential deals that passed screening or at the beginning of the DD phase. The purpose of these meetings is to help fill a round, expedite a closing, and save the CEO from extended road shows. The screening sessions are open and viewed by accredited investors from these respective groups. So far, 30-50% of those presenting have received additional funding from these investors (totalling \$23 million)
- Collectively, the angel groups participating in ASN represent over 1,500 angels, and more than \$1 billion in direct investment




Angel Syndication Network (ASN) funded \$5.1 million in 10 companies in 2023 – which was 25% of those screened:


- CryptoStop (Frontier Angels) a ransomware detection and response software
- Flow Aluminum (New Mexico Angels) Aluminum-CO2 battery for EVs, drones and storage that also does Direct Air Capture
- Healionics (Keiretsu) safer, more reliable means of bloodstream access for dialysis in patients with kidney failure
- Hilltop Bio (Frontier Angels) cell-signaling technology for veterinary market to help turbo charge the immune system to normalize and heal damaged tissue
- LIMBER Prosthetics & Orthotics (TCA VG) next generation of functional and accessible prosthetic devices
- MessageDesk (Reno Seed Fund) a shared inbox for text messaging that gives companies the ability to text as a team
- PredxBio (Keiretsu) explainable Al-powered spatial analytics software platforms to decipher complex cancer biology
- Princeton Identity (Golden Seeds) biometric identity management providing solutions for Access Control, Point of Sales, Time and Attendance
- Smart Response Technologies (Angel Round Table) Al public safety SaaS platform designed to maximize efficiency and speed for first responders

This greater syndication activity through ASN coupled with virtual screening and remote due diligence has shifted the geographic mix to more companies based outside of Southern California since 2020

- Traditionally, the mix has been 85% 90% in Southern California where TCA's members can be actively involved in mentoring and governing
- Due to Covid-19, the formation of ASN, the shift to virtual screening and due diligence, and the addition of virtual members across the USA, more than 50% of TCA deals are now outside SoCal providing increased geographical diversification
- 54% of all deals and 59% of all investment were outside SoCal in 2023
- In contrast, ACA Benchmarks show a much greater concentration on local funding




ACA BENCHMARKS BY GEOGRAPHY MIX OF DOLLARS




Investments in Massachusetts and New York were the largest concentrations outside Southern California

- Southern California represented 41% of the investment and 46% of the companies
- Massachusetts was 13% of the investment and 9% of the companies
- New York was 10% of the investment and 11% of the companies
- Northern California was 7% of the investment and 3% of the companies
- Other states were 29% of the investment and 31% of the companies
- There were no International deals in 2023





ACA BENCHMARKS
BY GEOGRAPHY
MIX OF DOLLARS



Annual chapter funds brought significant incremental capital to entrepreneurs and diversification for members


- \$5.7 million from TCA's four network funds supplemented \$5.2 million in direct investment from members
- 26 of TCA's 32 deals in 2023 received investment from at least one network fund
- Direct member investment in 2023 declined significantly, reflecting the environment
- TCA now targets completing due diligence and making a fund decision within 30 days, after which individual members invest alongside the funds
- The addition of the network funds has been a significant factor in bringing more capital to each company and more diversification to our members






TCA funding continues to be more likely when initial products/services are already developed and there is evidence of customer traction

- 59% of investments in 2023 were in companies with revenue and those seeking expansion capital, compared to 51% for ACA Benchmarks. This is driven by:
 - Companies are launching products/services earlier with MVPs (Minimum Viable Products) before seeking investment
 - Investors at this downturn stage of the investment cycle expect companies to be closer to breakeven in order to survive the anticipated downturn



For companies where specific revenue numbers were available, 84% had less than \$3 million in revenue in 2023


- Investors are seeking safety in developed products and proof there are customers –
 there was a dramatic shift from 58% with no revenue in 2022 to 18% in 2023
- ACA Benchmarks have also shifted dramatically away from no revenues from 51% with no revenue in 2022 to 30% in 2023
- There also was notable growth in companies with revenue over \$5 million representing 11% of TCA's funding and 12% of ACA Benchmark funding




TCA's investment focus continues to be on "seed" deals

- 66% of deals and 57% of investments in 2023 were **Seed** compared to 68% of deals and 76% of investments in 2022
- Some of this bias towards earliest stage deals has been the pursuit of lower valuations associated with Seed activity, since later rounds have been increasingly at less attractive valuations
- Series A represented 25% of deals and 25% of investments in 2023
- Series B & up represented 9% of deals and 17% of investments in 2023, a change from 9% of deals and 7% of investments in 2022

2016-2023 TCA INVESTMENT





Source: TCA Venture Group; Angel Capital Association Angel Funders Report - click here for full report

* Seed includes bridge to A

2016-2023 TCA INVESTMENTS


BY STAGE OF ROUND

2022

2023


Most investments in 2023 continue to be either Preferred Equity or Convertible Debt that converts into Preferred Equity

- The 30% invested in Preferred Equity is a significant decline from 50% in 2022
- SAFEs increased to 22% of deals and investments
- However, the prevalence of convertible notes (a combined 60% of the investment total) remains concerning to some because it limits long-term returns due to 1) less initial lift in valuation before Series A and 2) fewer deals will realize QSBS Section 1202/Section 1244 favorable tax treatment




TCA members take an active role in governance in 66% of the investments in 2023 – a dramatic increase from 37% in 2022

- For 66% of TCA's 2023 companies, there is a TCA member serving as either a board member or observer; in 2022 this was only 37%
- This is much higher than ACA's comparable benchmark of 47%
- Recent studies from other angel groups show returns tend to be higher with board involvement by members (<u>click here</u>)



Headcount of funded companies shifted to larger teams

- The percentage of funding going to companies with 1 4 FTEs dropped from 53% to 33% in 2023, reflecting a higher bar and greater maturity before funding. This parallels the shift to fewer companies without revenue
- Funding in companies with 50 99 FTEs increased from 0% to 9%




Traction among members deciding to invest directly in the most popular deals increased significantly at TCA VG

- Funding of deals with more than 20 TCA VG members participating increased from 6% in 2022 to 26% in 2023
- Funding of deals with 1 4 TCA VG members participating declined from 58% in 2022 to 37% in 2023




Syndication has become the norm, with 89% of deals involving other funding sources from angel groups

- Angel syndication grew from 55% in 2022 to 89% in 2023
- This trend is apparent in the ACA Benchmarks, which grew from 48% in 2022 to 59% in 2023
- But ACA Benchmarks in 2023 still show 31% involving no syndication compared to only 11% at TCA



While Angel Syndication is increasing, involvement of VC's and Strategics is decreasing


- VC's and Strategics fell from 73% of the amount invested in 2022 to 37% in 2023
- This reflects VC's scaling back new investments in Series A during the current downturn, as they have done in previous downturns
- TCA VG is helping fill in the gap due to the retrenchment of VCs




TCA VG funding was a larger portion of each round, and VC funding was lower

- In terms of dollar funding, TCA VG and other angel groups contributed a larger percentage of funding in 2023 – increasing from 27% in 2022 to 49% in 2023
- VC share of investment dropped from 54% to only 10%
- This shift is not unusual since VCs tend to cut back more aggressively on funding new companies during a downcycle, focusing instead on sustaining existing portfolio
- Funding by Strategics also dropped from 5% to 2%, reflecting the broader phenomenon of less M&A activity during the downcycle






2022-2023 TCA INVESTMENTS BY FUNDING SOURCE MIX OF DOLLARS



Valuations at time of TCA investment continue to increase above historical levels – this hopefully will reverse in 2024


- 13% of TCA's investments in 2023 were in companies with valuations below \$6 million, continuing a steady decline since 61% in 2016
- The long-term "sweet spot" for angel investing has been deals valued at \$1-3 million


 this declined to 3% of investment from 18% in 2016
- The 2023 valuation mix for TCA VG has less investment above \$20 million compared to ACA Benchmarks




More on Valuation Trends ...

- The median valuation eased a bit to \$8.8 million from \$10 million in 2022 but has still not dropped as much as later stage valuations and exits
- The spread in valuations remains the 80th percentile is 1.8 times the median
- New deals moved higher than follow-ons, driven partly by flat or down rounds, and partly because new deals had higher valuation due to more significant revenues
- Series B valuations dropped dramatically, reflecting market forces for later stages











More on Valuation Trends ...

- The overall medians for TCA VG in the past three years are mostly consistent with ACA Benchmarks
- Seed valuations generally track ACA Benchmarks
- However, Series B and later valuations for TCA are significantly less than ACA
 Benchmarks perhaps because the ACA deals have been more Series C and later










TCA'S 2023 Investment of \$10.9 million was part of a total of \$61 million into those 32 Companies

- TCA funding for new companies in 2023 averaged \$367k per company and 24% of the total round – higher than the ACA benchmark of \$252k
- TCA funding for follow-on companies in 2023 averaged \$305k per company and 16% of the total round – higher than the ACA benchmark of \$233k
- Syndication was critical, and TCA helps with that through ASN and our relationships
- The median total round size in 2023 for new was \$1.5 million (down from \$1.8 million in 2022) and for follow-on was \$1.3 million (down from \$2.6 million in 2022)

AVERAGE TCA FUNDING PER COMPANY



^{*}Note: Angel Capital Association Angel Funders Report – click here for full report

Tips for Entrepreneurs Going Forward

Dramatic drops in later stage exit activity and valuations, a weak IPO market, and VCs collapsing back to support their existing portfolio companies all translate into a challenging funding environment. But early stage investors like TCA VG continue to invest in great companies.

Our advice to smart entrepreneurs at this stage in the cycle is to be well prepared:

- Get realistic about valuation and don't look to historical averages. Any investment will be hard, and overpricing can be fatal if it leaves you underfunded or unable to secure follow-on funding a year or two in the future without a downround
- Maintain a healthy runway. In the next year or two, more good companies will likely fail for lack of financing than for all other reasons combined
- If you are lucky enough to attract funding, raise as much money as you can in the current round and don't be concerned about dilution. You won't regret it later
- Stay focused. Spend wisely and frugally. If the next dollar you spend doesn't make for a
 better product or better customer experience, don't spend it
- Seek investors who can provide you with experience, guidance and contacts that can help you navigate the challenges ahead (rather than those that are willing to offer the highest valuation), and listen to your advisers

Tips for Angels Going Forward

Our advice to smart angels at this stage in the cycle is to be well prepared:

- Accelerate funding of companies who embrace more realistic valuations particularly companies which can achieve breakeven with the funds raised in the current round
- Be cautious about investing in companies that cannot achieve breakeven with funds from the current round if future funding sources do not materialize
- Invest in funds if you have a limited amount of capital to deploy giving you the benefits of diversification that is so important in this class of investment. Supplement the investment in funds with direct investment in areas/markets in which you or your group have expertise
- Join a trusted angel group to access quality deal flow and the expertise of others in due diligence and mentorship of the companies moving forward
- Learn from other experienced angels by participating in the Angel Capital Association's
 Angel University, webinars and annual ACA Summit conference. TCA VG members
 are all members of ACA, and have access to those benefits.
- Be patient you'll likely have more failures than successes, and the successes will typically come later. But a few of the successes should more than compensate for the shutdowns and yield an overall attractive portfolio return

FOR MORE INFORMATION

WEBSITE: https://www.tcaventuregroup.com

Apply for funding: https://tcaventuregroup.com/apply-for-funding

Apply for membership: https://tcaventuregroup.com/angels

Learn about Licensing: David Friedman at dfriedman@prodigy.net

Questions about the Annual Report: John Harbison at john_harbison@techspin.com

Linked In: https://www.linkedin.com/company/659209

X/Twitter: https://x.com/TCAventuregroup

Facebook: https://www.facebook.com/tcaventuregroup

Thank You to TCA's Sponsors!













































Serving You Since 1993







MOSSADAMS

remotish.





















Smith Fidler





















